Abstract: The present invention relates to novel amino acid sequences of peptides derived from HPV16 that are able to bind to MHC complexes of class II, and elicit an immune response. The present invention further relates to pharmaceutical products, such as vaccines and T-cells, based on said epitopes.
Type:
Application
Filed:
December 1, 2014
Publication date:
October 27, 2016
Applicant:
Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts
Abstract: The present invention relates to the use of Rspondins, particularly Rspondin2 (Rspo2) or Rspondin3 (Rspo3) or Rspondin nucleic acids, or regulators or effectors or modulators of Rspondin, e.g. Rspo2 and/or Rspo3 to promote or inhibit angiogenesis and/or vasculogenesis, respectively. The invention is based on the demonstration that Rspo3 and Rspo2 are angiogenesis promoters, and the identification of Rspo2 and 3 as positive regulators of vascular endothelial growth factor (VEGF). These results indicate a major role for Rspondins, particularly Rspo3 and/or Rspo2 in the signaling system during angiogenesis. The invention also relates to the use of regulators or effectors or modulators of Rspondin3, including agonists and antagonists, in the treatment of conditions where treatment involves inhibiting or promoting angiogenesis and/or vasculogenesis.
Type:
Grant
Filed:
August 7, 2014
Date of Patent:
January 5, 2016
Assignee:
Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts
Inventors:
Christof Niehrs, Olga Kazanskaya, Bisei Okawara
Abstract: The present invention relates to the use of Rspondins, particularly Rspondin2 (Rspo2) or Rspondin3 (Rspo3) or Rspondin nucleic acids, or regulators or effectors or modulators of Rspondin, e.g. Rspo2 and/or Rspo3 to promote or inhibit angiogenesis and/or vasculogenesis, respectively. The invention is based on the demonstration that Rspo3 and Rspo2 are angiogenesis promoters, and the identification of Rspo2 and 3 as positive regulators of vascular endothelial growth factor (VEGF). These results indicate a major role for Rspondins, particularly Rspo3 and/or Rspo2 in the signaling system during angiogenesis. The invention also relates to the use of regulators or effectors or modulators of Rspondin3, including agonists and antagonists, in the treatment of conditions where treatment involves inhibiting or promoting angiogenesis and/or vasculogenesis.
Type:
Grant
Filed:
October 8, 2013
Date of Patent:
January 6, 2015
Assignee:
Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts
Inventors:
Christof Niehrs, Olga Kazanskaya, Bisei Okawara
Abstract: The present invention relates to fusion polypeptides including (a) a binding site for a cytoskeleton component and (b1) an effector protein or the catalytic domain thereof or (b2) a binding site for the effector protein, and nucleic acid sequences encoding the fusion polypeptides. Moreover, various therapeutic uses of the fusion polypeptides are described, e.g., the treatment of diseases associated with the presence of an aberrant cell population, preferably cancer or AIDS.
Type:
Grant
Filed:
July 1, 2009
Date of Patent:
December 3, 2013
Assignee:
Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
Abstract: The present invention is concerned with means and methods for diagnosing or treating HPV associated neoplasia or tumors. Specifically, it relates to a peptide comprising an amino acid sequence motif as shown in SEQ ID No: 1. Moreover, contemplated by the present invention are fusion polypeptides, polynucleotides, vectors and host cells based on said peptide. Furthermore, the peptides, fusion polypeptides, polynucleotides, and vectors are suitable as pharmaceutical compositions for treating HPV associated neoplasia or tumors. The peptides and fusion polypeptides are also suitable as diagnostic compositions for diagnosing HPV associated neoplasia or tumors. The present invention also refers to a method of identifying a compound capable of binding to the HPV E6 protein. Finally, a kit is provided for carrying out the aforementioned diagnosis or compound identification.
Type:
Grant
Filed:
April 7, 2009
Date of Patent:
December 3, 2013
Assignee:
DKFZ Deutsches Krebsforschungszentrum, Stiftung des offentlichen Rechts
Inventors:
Felix Hoppe-Seyler, Karin Hoppe-Seyler, Susanne Kintscher
Abstract: The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.
Type:
Grant
Filed:
February 6, 2012
Date of Patent:
November 12, 2013
Assignees:
Deutsches krebsforschungszentrum Stiftung des Offentlichen Rechts, Medigene AG
Inventors:
Daniela Kelm, Peter Altevogt, Gerhard Moldenhauer, Frank Brietling, Achim Krueger, Silke Wolterink, Sandra Luettgau, Ulrich Moebius, Yi Li, Susanne Sebens, Heiner Schaefer
Abstract: The present invention relates to the use of Rspondins, particularly Rspondin2 (Rspo2) or Rspondin3 (Rspo3) or Rspondin nucleic acids, or regulators or effectors or modulators of Rspondin, e.g. Rspo2 and/or Rspo3 to promote or inhibit angiogenesis and/or vasculogenesis, respectively. The invention is based on the demonstration that Rspo3 and Rspo2 are angiogenesis promoters, and the identification of Rspo2 and 3 as positive regulators of vascular endothelial growth factor (VEGF). These results indicate a major role for Rspondins, particularly Rspo3 and/or Rspo2 in the signaling system during angiogenesis. The invention also relates to the use of regulators or effectors or modulators of Rspondin3, including agonists and antagonists, in the treatment of conditions where treatment involves inhibiting or promoting angiogenesis and/or vasculogenesis.
Type:
Grant
Filed:
December 1, 2011
Date of Patent:
November 12, 2013
Assignee:
Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
Inventors:
Christof Niehrs, Olga Kazanskaya, Bisei Okawara
Abstract: The invention discloses a method of prenatal diagnosis comprising the step of isolating exosomes from an isolated fluid, wherein the exosomes are identified by biomarker detection. Furthermore, the invention discloses the isolation of exosomes from an isolated fluid and the use of a biomarker, particularly CD24 to isolate exosomes from an isolated fluid.
Type:
Grant
Filed:
August 1, 2008
Date of Patent:
October 29, 2013
Assignee:
DKFZ Deutsches Krebsforschungszentrum, Stiftung des Offentlichen Rechts
Abstract: Provided is a method of treating a patient having an inflammatory disease by using a compound which inhibits the complex I-mediated ROS production, a medicament containing such compound and methods for screening for such compounds.
Type:
Grant
Filed:
September 5, 2007
Date of Patent:
October 22, 2013
Assignee:
Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
Inventors:
Karsten Guelow, Marcin Kaminski, Michael Kiessling, Peter H. Krammer
Abstract: The present invention relates to a process for linking two molecules by means of a Diels Alder reaction with inverse electron requirement (DARinv), comprising the following steps: reaction of a (a) triazine or tetrazine with one or more electron-attracting substituents on the ring as a diene component, the electron-attracting substituents being selected from: COOR C(O)NR2 CX3 (X=halogen) halogen CN SO2—R or SO3—R PR2 wherein R?H, alkyl, aryl, heterocycle, which in turn may be substituted, where appropriate, with alkyl, OH, SH, halogen, aryl, heterocycle, nitro, carboxyamido or amine group.
Type:
Grant
Filed:
June 18, 2007
Date of Patent:
October 8, 2013
Assignee:
Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
Inventors:
Manfred Wiessler, Eduard Müller, Peter Lorenz, Christian Kliem, Heinz Fleischhacker
Abstract: A sensor means is employed to sense a distance to the surface of a subject to be examined, so that a range image may be acquired. Intensity information may be acquired alongside the distance information. The distance information and intensity information may be evaluated to track the pose of the sensor means relative to the surface of the subject to be examined, so that anatomical data related to said subject may be displayed as seen from the position and/or orientation of the sensor means or display means. By moving the sensor means or display means along the surface of the subject to be examined, such as a patient in a hospital environment, the user hence gets the impression of being able to look directly into the human body.
Type:
Application
Filed:
May 10, 2013
Publication date:
September 19, 2013
Applicant:
Deutsches Krebsforschungszentrum Stiftung des offentlichen Rechts
Inventor:
Deutsches Krebsforschungszentrum Stiftung des offentlichen Rechts
Abstract: The present invention relates to an inhibitor protein of the wnt signal path, a DNA encoding such a protein and a process for the preparation of such a protein. In addition, this invention concerns the use of the DNA and the protein as well as antibodies directed against the protein.
Type:
Grant
Filed:
November 20, 2006
Date of Patent:
September 17, 2013
Assignee:
Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
Abstract: The present invention relates to an inhibitor protein of the wnt signal path, a DNA encoding such a protein and a process for the preparation of such a protein. In addition, this invention concerns the use of the DNA and the protein as well as antibodies directed against the protein.
Type:
Grant
Filed:
January 19, 2011
Date of Patent:
June 11, 2013
Assignee:
Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
Abstract: The present invention relates to methods for the diagnosis of a brain tumor and for the estimation of a prognosis for patients having a brain tumor using the presence/absence of a particular IDH1 mutation as a marker.
Type:
Grant
Filed:
December 14, 2009
Date of Patent:
February 5, 2013
Assignee:
Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts and Ruprecht-Karls-Univeristat Heidelberg
Inventors:
Christian Hartmann, Andreas von Deimling, Hanswalter Zentgraf, David Capper, Guido Reifenberger, Michael Weller, Wolfgang Wick
Abstract: The invention relates to an imaging method for simultaneously determining in vivo distributions of bioluminescent and/or fluorescent markers and radioactive markers at identical projection angles, the distribution of the bioluminescent and/or fluorescent markers being determined by separate detection of photons having a first average energy, which are emitted by the bioluminescent and/or fluorescent markers, by means of at least one first detector and the distribution of the radioactive markers being determined by simultaneous separate detection of photons having a second average energy, which are emitted by the radioactive markers, by means of at least one second detector.
Type:
Grant
Filed:
June 11, 2003
Date of Patent:
January 29, 2013
Assignee:
Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts
Abstract: The present invention is concerned with the therapy of neuroblastoma and related diseases. Specifically, the present invention relates to a method for treating or preventing neuroblastoma comprising administering to a subject a therapeutically effective amount of bone morphogenetic protein 4 (BMP4). Preferably, said BMP4 is applied together with chemotherapy and/or radiation therapy.
Type:
Grant
Filed:
February 4, 2009
Date of Patent:
January 29, 2013
Assignee:
DKFZ Deutsches Krebsforschungszentrum, Stiftung des Offentlichen Rechts
Abstract: Described is a pharmaceutical composition comprising (a) a parvovirus and (b) a cytokine, preferably IFN-?, and the use of said composition for treatment of cancer, e.g., a brain tumor.
Type:
Application
Filed:
May 19, 2010
Publication date:
August 23, 2012
Applicants:
Ruprecht-Karls-Universitaet Heidleberg, Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts
Abstract: The present invention relates to a composition useful for the diagnosis and therapy of diseases associated with aberrant expression of the gene encoding the receptor Kremen 1 and/or Kremen 2 e.g. tumors or diseases of the kidneys, bones and eyes, lipid and glucose metabolism and obesity. The present invention also relates to a pharmaceutical composition containing a compound which is capable of modifying (a) the expression of the gene encoding Kremen 1 and/or Kremen 2 or (b) the activity of the Kremen 1 and/or Kremen 2 receptor.
Type:
Grant
Filed:
April 5, 2011
Date of Patent:
July 24, 2012
Assignee:
Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts
Abstract: The invention relates to a method for determining the ratio of two distinct target-peptides or polynucleic acids comprising: a) obtaining a sample containing said two distinct target-peptides or polynucleic acids, b) providing a precursor-peptide or precursor-polynucleic acid, comprising the two distinct target-peptides or -polynucleic acids in a known ratio, wherein the two distinct target-peptides or -polynucleic acids are connected by a cleavage site, c) cleaving the precursor-peptide or precursor-polynucleic acid at the cleavage site to obtain a standard with the known ratio of the two distinct target-peptides or -polynucleic acids, d) detecting a signal of each distinct target-peptide or -polynucleic acid of the standard in an analyzer, comparing the signals with the known ratio and determining a correction factor, e) detecting the signal of each distinct target-peptide or -polynucleic acid of the sample in the analyzer and f) determining the ratio of the two distinct target-peptides or -polynucleic acid
Type:
Grant
Filed:
April 25, 2007
Date of Patent:
July 10, 2012
Assignee:
DKFZ Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts
Abstract: The present invention relates to a composition comprising an oligonucleotide mixture. Moreover, the present invention relates to the use of said oligonucleotide mixture for diagnosing different HPV genotypes in a sample of a subject. Further encompassed is a method for diagnosing different HPV genotypes in a sample of a subject and a kit carrying out said method.
Type:
Grant
Filed:
August 26, 2008
Date of Patent:
June 19, 2012
Assignee:
DKFZ Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts
Inventors:
Markus Schmitt, Tim Waterboer, Michael Pawlita